Impact of Hepatectomy on HCC Recurrence

Impact of Major Hepatectomy on Recurrence After Resection of Hepatocellular Carcinoma at China Liver Cancer Staging (CNLC) Stage : a Propensity Score Matching Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06390228

Acronym

HCC

Enrollment

197

Registered

2024-04-30

Start date

2019-01-01

Completion date

2023-08-01

Last updated

2024-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma Stage I, Recurrence

Keywords

Hepatocellular Carcinoma, recurrence, hepatectomy

Brief summary

Hepatectomy is the first option for the treatment of hepatocellular carcinoma(HCC) at CNLC Ib stage. HCC patients who undergo curative hepatectomy may experience varying remnant liver volumes and thus leads to different oncological outcomes.

Detailed description

Patients with hepatocellular carcinoma (HCC) who undergo curative hepatectomy may experience varying remnant liver volumes. The investigators aimed to evaluate whether the extent of liver resection has an effect on postoperative recurrence in HCC patients. A retrospective analysis was conducted on 197 patients who underwent hepatectomy for a solitary HCC lesion measuring ≥5 cm between January 2019 and June 2022. Patients were divided into major hepatectomy (MAH) group (n=70) and minor hepatectomy (MIH) group (n=127) based on the extent of liver resection. Recurrence-free survival (RFS) was compared between the two groups. Propensity score matching was employed to mitigate potential biases in this research.

Interventions

PROCEDUREMajor hepatectomy

the extent of liver resection

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* histologically confirmed solitary HCC with a size of ≥5 cm * Eastern Cooperative Oncology Group score of 0 or 1 * preoperative indocyanine green retention rate at 15 minutes ≤15% and Child-Pugh A classification * no evidence of vascular invasion or extrahepatic disease.

Exclusion criteria

* not diagnosed with HCC or had an HCC measuring \<5 cm * had confirmed tumor metastases or macrovascular invasion based on radiological examinations * died within 90 days after surgery were excluded

Design outcomes

Primary

Measure	Time frame	Description
recurrence-free survival	2019.1-2023.8	the time from the time of radical surgery to the time of HCC recurrence

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026